We are proud to announce that Oxford Immune Algorithmics (OIA), creator of Algocyte, is part of the Creative Destruction Lab-Toronto Health Diagnostics Stream’s 2020/21 graduating cohort, and was one of the top two performers in the CDL-- Atlanta Recovery Stream 2020/2021. The nine-month odyssey that started in Atlanta, U.S. and ended in Toronto, Canada, marks not only a significant milestone for OIA, but one that has positively altered the trajectory of the company.
The OIA team, led by its founders, interacted with leading academics and business leaders in medicine, business and science, who engaged and challenged us through intensive, multiple-to-one and one-on-one sessions. The CDL program works as a marketplace with four checkpoints where high calibre mentors, including former directors of national health institutions, venture capitalists and top academics, vote to save start-ups from elimination, helping them to make it through to the next session.
Around 400 worldwide start-ups, ready to help the world recover from the pandemic, applied to join the CDL Recovery stream in 2020. Twenty were selected and only two graduated, one of which was OIA. We are honoured to be acknowledged and chosen by such a distinguished group of world leaders.
With the help of CDL and its mentors, OIA has reached several new milestones, including establishing a biochemical lab in Atlanta, in partnership with Georgia Tech, to advance our microfluidics technology; fundraising and closing a £5.1M seed round led by Medtech AI; and welcoming Pam Winsor, former CMO of Medtronic Canada, who joined OIA's board as Chair.
The Creative Destruction Lab is a seed-stage accelerator that began in 2012 at the University of Toronto’s Rotman School of Management and currently runs ten accelerators in the U.S, Europe and Canada. In addition, it is an engine for scaling and funding deep tech companies, supporting CDL’s “innovative mindset,” and one of its key focus areas is computational health. The not-for-profit is funded by the Canadian government’s Strategic Innovation Fund and includes accelerators from future and space tech, artificial intelligence, blockchain, smart cities, health and quantum computing.
Oxford Immune Algorithmics (OIA) is an award-winning Deep MedTech company incubated by the University of Oxford with a mission to rid the world of preventable diseases. It operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.
OIA, key partner in UK’s EPSRC research network, awarded grant to explore the future of blood testing
Oxford Immune Algorithmics' (OIA) continues to be acknowledged both internationally and in the U.K. The recent announcement of the award of an EPSRC Future blood testing for inclusive monitoring and personalised analytics network’ grant cited OIA’s role as a key partner, “essential in an interdisciplinary remote blood-testing monitoring network”. The EPSRC is the funding arm for Engineering and Physical Scientific research in the U.K.
The project funded by the grant, spearheaded by Dr. Weizi Li, Deputy Director of the Informatics Research Centre at the Henley Business School, University of Reading, aims to explore solutions that will enable patients and health professionals to carry out their blood tests remotely, greatly accelerating decision-making, the processing of blood samples, and the delivery of diagnoses, all of which have been made more urgent than ever by Covid-19.
Clinical healthcare continues to face challenges in obtaining and processing blood samples outside of clinical platforms, and reducing labour-intensive and manual tweaking, which are not suited for home blood monitoring. All of these factors significantly hamper the timely analysis of blood samples. Capturing patients' sequential data over time to compile information crucial to the early detection of complex diseases has been identified as the only way to manage chronic health conditions.
In the U.K., more than 500 million biochemistry and 130 haematology tests are conducted annually, with 95% of clinical pathways requiring patients to have access to timely, cost-effective pathology services. Inefficient handling of blood testing and analysis translates into inefficient and late diagnoses of many illnesses, and to opportunities lost due to a lack of knowledge of disease progression and the many attendant health complications.
The interdisciplinary network will look at the entire spectrum of blood testing technologies to “raise awareness, generate big ideas, and highlight blood testing solutions for remote, inclusive, rapid, affordable and personalised blood monitoring”. The network's formation signals a shift in the healthcare industry and acknowledges deficits in the current health system. The network will explore three principal areas: remote monitoring, I.C.T., and personalised data and A.I. to monitor diseases such as cancer, autoimmune diseases, general and pre-operative care.
The EPSRC aims to maintain the U.K.'s leading position in research and training by providing opportunities for researchers to collaborate. Partners in the network include Stanford University, Cambridge University Hospitals, M.I.T., Karolinska Institute, and the Imperial College London.
Oxford Immune Algorithmics (OIA) is an award-winning Bio and MedTech company incubated by the University of Oxford with a mission to rid the world of preventable diseases. It operates multi-nationally to build technology that moves healthcare away from its reliance on population-wide symptom pattern matching toward value-based precision medicine and personalised diagnostics.